Skip to content

Study · Observational study · n = 545 · 2020

4 results

Weight Outcomes With Empagliflozin as Compared With Liraglutide in Veterans With Type 2 Diabetes Mellitus.

Grabarczyk TR, Wissman NK

The Annals of pharmacotherapy10 Apr 2020Cited by 3 (Europe PMC)

PMID32274930 (opens in a new tab)DOI10.1177/1060028020915791 (opens in a new tab)PepBankPUB-32274930
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In veterans with type 2 diabetes and overweight or obesity, weight loss at 1 year with liraglutide did not differ significantly from empagliflozin.

    In plain wordsIn veterans with type 2 diabetes and overweight, liraglutide and empagliflozin led to similar weight loss after 1 year.

    Peptide
    Liraglutide
    Outcome
    No significant changeWeight change at 1 year, liraglutide versus empagliflozin
    Study

    n = 545

    Comparator
    Empagliflozin
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    Weight change
    −2.17 kg
    liraglutide
    Weight change
    −2.81 kg
    empagliflozin

    Source sentences

    Summary
    Weight loss was not significantly different between groups: -2.17 kg (95% CI: -2.91 to -1.42) in the liraglutide group (n = 298) and -2.81 kg (95% CI: -3.43 to -2.20) in the empagliflozin group (n = 247; P > 0.05).
    1 context sentence
    Summary · context
    This is an observational, multisite, cohort study of veterans with T2DM prescribed liraglutide or empagliflozin. Participants were prescribed either empagliflozin or liraglutide prior to November 1, 2017, had a hemoglobin A1C (A1C) ≥7.0%, had a body mass index ≥27 kg/m2, and we…
  2. 02HumanObservational studyEfficacy outcome

    In veterans with type 2 diabetes and overweight or obesity, body weight fell by 2.17 kg after 1 year in the liraglutide group.

    In plain wordsIn veterans with type 2 diabetes and overweight, people on liraglutide lost about 2 kg over 1 year.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight change at 1 year, liraglutide group
    Study

    n = 298

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    Weight change
    −2.17 kg
    liraglutide

    Source sentences

    Summary
    -2.17 kg (95% CI: -2.91 to -1.42) in the liraglutide group (n = 298)
    1 context sentence
    Summary · context
    This is an observational, multisite, cohort study of veterans with T2DM prescribed liraglutide or empagliflozin. Participants were prescribed either empagliflozin or liraglutide prior to November 1, 2017, had a hemoglobin A1C (A1C) ≥7.0%, had a body mass index ≥27 kg/m2, and we…
  3. 03HumanObservational studyEfficacy outcome

    In veterans with type 2 diabetes and overweight or obesity, the change in A1C with liraglutide did not differ from empagliflozin.

    In plain wordsIn veterans with type 2 diabetes and overweight, liraglutide and empagliflozin lowered A1C by similar amounts.

    Peptide
    Liraglutide
    Outcome
    No significant changeA1C change, liraglutide versus empagliflozin
    Study

    n: not reported in source

    Comparator
    Empagliflozin
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    A1C change
    −0.83%
    liraglutide
    A1C change
    −0.71%
    empagliflozin

    Source sentences

    Summary
    There was no difference in change in A1C between liraglutide (-0.83%; 95% CI: -1.05% to -0.62%) and empagliflozin (-0.71%; 95% CI: -0.89% to -0.53%; P > 0.05).
    1 context sentence
    Summary · context
    This is an observational, multisite, cohort study of veterans with T2DM prescribed liraglutide or empagliflozin. Participants were prescribed either empagliflozin or liraglutide prior to November 1, 2017, had a hemoglobin A1C (A1C) ≥7.0%, had a body mass index ≥27 kg/m2, and we…
  4. 04HumanObservational studyEfficacy outcome

    In veterans with type 2 diabetes and overweight or obesity, A1C fell by 0.83% after 1 year in the liraglutide group.

    In plain wordsIn veterans with type 2 diabetes and overweight, A1C fell by 0.83 percentage points in people on liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseA1C change, liraglutide group
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    A1C change
    −0.83%
    liraglutide

    Source sentences

    Summary
    liraglutide (-0.83%; 95% CI: -1.05% to -0.62%)
    1 context sentence
    Summary · context
    This is an observational, multisite, cohort study of veterans with T2DM prescribed liraglutide or empagliflozin. Participants were prescribed either empagliflozin or liraglutide prior to November 1, 2017, had a hemoglobin A1C (A1C) ≥7.0%, had a body mass index ≥27 kg/m2, and we…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.